News Quantified

MRSN – mersana therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

2.6%

MISS

13.7%

MISS

-19.5%

BEAT

Form 4 Mersana Therapeutics, For: Jan 06 Filed by: Hack Andrew A. F.

Form 4 Mersana Therapeutics, For: Jan 06 Filed by: Hege Kristen

Form 4 Mersana Therapeutics, For: Jan 06 Filed by: Diaz Allene M.

Form 4 Mersana Therapeutics, For: Jan 06 Filed by: Dere Willard H

Form 4 Mersana Therapeutics, For: Jan 06 Filed by: Carvajal Alejandra

Top News Gainers

4/8 Mersana Therapeutics secures $65M capital raise [Seeking Alpha] 33.5%

1/16 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 22.7%

2/8 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 14.9%

11/27 Form 8-K Mersana Therapeutics, For: Nov 26 12.6%

2/28 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%

2/18 Mersana Therapeutics to Present at Upcoming Investor Conferences 9.1%

12/23 Form SC 13G Mersana Therapeutics, Filed by: Venrock Healthcare Capital Partners II, L.P. 9.1%

5/9 Form 10-Q Mersana Therapeutics, For: Mar 31 8.3%

10/10 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.1%

11/6 Form 8-K Mersana Therapeutics, For: Nov 06 7.0%

Top News Decliners

3/30 Form 8-K Mersana Therapeutics, For: Mar 30 -15.5%

3/14 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -13.8%

12/28 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -12.8%

3/12 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%

8/10 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%

4/9 Form 424B5 Mersana Therapeutics, -9.1%

4/29 Mersana Therapeutics to Host Conference Call Announcing First Quarter 2020 Financial Results and Business Updates -8.9%

4/20 Form DEF 14A Mersana Therapeutics, For: Jun 12 -8.8%

6/1 Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting -8.1%

6/12 Form 8-K Mersana Therapeutics, For: Jun 07 -7.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day